Bio-Rad Laboratories Inc. (BIO.B) on Wednesday reported a third-quarter loss of $341.9 million, after reporting a profit in the same period a ...

The outlook for full year 2025 remains unchanged at flat to 1% currency-neutral revenue growth, consistent with the Q2 update. Margins guidance is also unchanged. Q3 reported a slight revenue and ...

The company doesn't seem like it will generate pops in key fundamentals anytime soon.

Biodesix has expanded its collaboration with Bio-Rad Laboratories for the development and clinical validation of in vitro diagnostic (IVD) assays, designed to facilitate the identification of a ...

Biodesix, Inc., a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement ...

Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the ...

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...

The approval of the merger between Providus Bank and Unity Bank Plc effectively consummated the first merger under the ongoing banking recapitalisation. With barely six months to the deadline for the ...

Oct 14 (Reuters) - U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical (4502.T), opens new tab, deepening their ...

The firm is projecting a gradual recovery of the academic market in the face of ongoing funding uncertainties and a government shutdown.

The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...